for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Crinetics Pharmaceuticals Inc

CRNX.OQ

Latest Trade

16.42USD

Change

-0.29(-1.74%)

Volume

14,951

Today's Range

16.04

 - 

16.81

52 Week Range

14.46

 - 

36.28

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
16.71
Open
16.60
Volume
14,951
3M AVG Volume
1.45
Today's High
16.81
Today's Low
16.04
52 Week High
36.28
52 Week Low
14.46
Shares Out (MIL)
24.20
Market Cap (MIL)
405.59
Forward P/E
-8.16
Dividend (Yield %)
--

Latest Developments

More

Crinetics Pharmaceuticals Files For Mixed Shelf Of Up To $300 Mln

Crinetics Pharmaceuticals Inc Reports Quarterly Loss Per Share Of $0.51

Crinetics Pharmaceuticals Inc Posts Q4 Loss Per Share of $0.35 - SEC Filing

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Crinetics Pharmaceuticals Inc

Crinetics Pharmaceuticals, Inc. is a clinical stage pharmaceutical company. The Company is focused on the discovery and development of drugs to treat specialty endocrine diseases and endocrine-related tumors. It develops a pipeline of oral nonpeptide chemical entities that target peptide G protein coupled receptors (GPCRs) for the treatment of endocrine diseases. The Company’s lead product candidate is CRN00808 developed for the treatment of acromegaly. It also develops two other product candidates CRN02481 for hyperinsulinemia, and CRN01941 for the treatment of neuroendocrine tumors. CRN02481 and CRN01941 are both oral nonpeptide somastatin receptors that are in the pre-clinical stages of development. The company also conducts research programs on developing nonpeptide products for the treatment of Cushing’s disease.

Industry

Biotechnology & Drugs

Contact Info

10222 Barnes Canyon Rd Bldg 2

+1.858.4506464

https://www.crinetics.com/

Executive Leadership

Wendall Wierenga

Independent Chairman of the Board

R. Scott Struthers

President, Chief Executive Officer, Director

Marc Wilson

Chief Financial Officer

Stephen F. Betz

Vice President - Biology

Gina Ford

Vice President, Corporate Strategy and Commercial Planning

Key Stats

2.00 mean rating - 5 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2018

0.0K

2019(E)

0.0K
EPS (USD)

2018

-2.230

2019(E)

-2.054
Price To Earnings (TTM)
--
Price To Sales (TTM)
239.15
Price To Book (MRQ)
2.85
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
0.00
LT Debt To Equity (MRQ)
0.00
Return on Investment (TTM)
-34.67
Return on Equity (TTM)
-32.65

Latest News

Latest News

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up